Shionogi & Company Description
Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan.
It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug.
It also develops S-872600 an influenza nasal vaccine; S-875670 anCOVID-19 nasal vaccine; S-540956 a nucleic acid adjuvant; S-554110 a nontuberculous mycobacterial infection; S-337395 for RSV infections; S-892216 for COVID-19 therapeutics; Olorofim for invasive aspergillosis; cefiderocol for aerobic gram-negative bacterial infections and infectious diseases; S-268019 a COVID-19 prophylactic vaccine; S-268019 a prophylactic vaccine for COVID-19; ensitrelvir for COVID-19 treatment and prevention; baloxavir for influenza virus infection; S-365598 for HIV infection; and S-555739 for suppressing aggravation of COVID-19.
In addition, the company develops S-540956 for nucleic acid adjuvant; S-109802 for post-stroke spasticity; S-151128 for chronic pain; S-588210 and S-531011 for solid tumor; S-309309 for obesity; BPN14770 for Alzheimer’s disease and fragile X syndrome; S-588410 for bladder cancer; S-488210 for head and neck squamous cell carcinoma; S-005151 for Acute ischemic stroke and epidermolysis bullosa; Rizmoic for opioid-induced constipation; ADR-001 for decompensated liver cirrhosis; S-222611 for malignant tumor; S-812217 for depression; GRT7039 for pain associated with osteoarthritis of the knee; SDT-001 for inattentive ADHD; S-588410 for esophageal cancer; SR-0379 for cutaneous ulcer; and S-723595 for type 2 diabetes.
The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943.
Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.
| Country | Japan |
| Founded | 1878 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 4,959 |
| CEO | Isao Teshirogi |
Contact Details
Address: 1-8, Doshomachi 3-chome Osaka, 541-0045 Japan | |
| Phone | 81 6 6202 2161 |
| Website | shionogi.com |
Stock Details
| Ticker Symbol | SGIOF |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | April - March |
| Reporting Currency | JPY |
| ISIN Number | JP3347200002 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Isao Teshirogi Ph.D. | Chief Executive Officer, President and Chairman |
| Susumu Mitsumori | Vice President of Finance and Accounting Department |
| Dr. Ryuichi Kiyama Ph.D. | Senior Executive Officer and Senior Vice President of Administration Division |
| Takeshi Shiota Ph.D. | Corporate Officer and Senior Vice President of Corporate Quality Assurance, Ethics and Compliance Management Div. |
| Yoshimasa Kyokawa | Vice President of Corporate Communications and Secretary Office |
| Yoshihiro Furuya | Vice President of General Marketing and Compliance Officer of Corporate GXP Compliance Office |
| Kohji Hanasaki Ph.D. | Senior Executive Officer and Senior Vice President of Supply Supervisory Unit |
| Dr. John A. Keller Ph.D. | Senior Executive Officer and Senior Vice President of Research & Development Supervisory Unit |
| Kazuhiro Hatanaka | Senior Executive Officer and Senior Vice President of Corporate Strategy Division |
| Akira Kato Ph.D. | Senior Executive Officer and President of Shionogi Pharma Co., Ltd |